Zydus announces USFDA Orphan Drug Designation to Usnoflast for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Patients and care partners may find once every four weeks maintenance dosing easier The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application ...

Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...

A machine learning analysis of gene activity in spinal cord samples from people with amyotrophic lateral sclerosis (ALS) revealed new genes associated with the neurodegenerative disorder, a study ...

Natco Pharma has received US FDA approval for its generic version of Everolimus tablets for oral suspension, indicated for patients with tuberous sclerosis complex. The drug is a generic version of ...

EBITDA for Q2 increased by 27.5% year-on-year to ₹1,461.4 crore, with EBITDA margins expanding by 170 basis points to 27.9%.

New York received the highest mark on the ALS Association’s latest report cards, which grade states based on how effectively they’re using public policy to serve the amyotrophic lateral sclerosis (ALS ...

ICICI Pru Regular Savings Fund (G) 6.13 62,263 0.19 ICICI Pru Regular Savings Fund (IDCW-M) 6.13 62,263 0.19 ICICI Pru Regular Savings Fund (IDCW-Q) 6.13 62,263 0.19 ...

EBITDA for Q2 increased by 27.5% year-on-year to ₹1,461.4 crore, with EBITDA margins expanding by 170 basis points to 27.9%.

Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 ,inter alia, to consider and approve unaudited financial results for the ...

1. Current NAV: The Current Net Asset Value of the Mirae Asset Nifty India Manufacturing ETF FoF - Regular Plan as of Jan 30, 2025 is Rs 16.48 for Growth option of its Regular plan. 2. Returns: Its ...